Cyclopharm Limited (ASX: CYC)

Market Cap	236.72M
Revenue (ttm)	24.06M
Net Income (ttm)	-9.32M
Shares Out	111.14M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,237
Average Volume	158,019
Open	2.130
Previous Close	2.130
Day's Range	2.100 - 2.150
52-Week Range	1.330 - 2.320
Beta	0.72
RSI	70.83
Earnings Date	Feb 24, 2025

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders,...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1986
• Employees: 87
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYC

Financial Performance

In 2023, Cyclopharm's revenue was 27.14 million, an increase of 9.19% compared to the previous year's 24.85 million. Losses were -4.70 million, -28.90% less than in 2022.